AMICUS THERAPEUTICS, INC. — Director's Dealing 2020

Sep 30, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMICUS THERAPEUTICS, INC. (FOLD)
CIK: 0001178879
Period of Report: 2020-09-28

Reporting Person: Campbell Bradley L (Director, Chief Operating Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-09-28	Common Stock	M	24782	$2.52	Acquired	363546	Direct
2020-09-28	Common Stock	S	24782	$13.8893	Disposed	338764	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-09-28	Stock Options (right to buy)	$2.52	M	24782	Disposed	2023-06-18	Common Stock (24782)	Direct

Footnotes

F1: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.69 to $14.01 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: All of the options were fully vested and exercisable as of the transaction date.